Nuchal translucency screening: How do women actually utilize the results?

被引:6
作者
Caughey, Aaron B.
Musci, Thomas J.
Belluomini, Jenny
Main, Denise
Otto, Carl
Goldberg, James
机构
[1] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA
[2] Calif Pacific Med Ctr, Dept Obstet & Gynecol, San Francisco, CA USA
关键词
nuchal translucency; prenatal diagnosis; down syndrome; prenatal screening;
D O I
10.1002/pd.1617
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective To examine how women use the nuchal translucency (NT) risk adjustment in decision-making for invasive prenatal diagnosis. Study Design Retrospective cohort study of 1083 consecutive NT screening exams. A screen-positive test was defined as a risk >= 1/300. Primary outcome was what proportion of screen-positive or screen-negative women chose to undergo chorionic villus sampling or amniocentesis. Results Of the women tested, 79% (858/1083) were >= 35-years-old and 88% (756/858) of these women had a decrease in age-related risk after NT. Of the screen-negative women, 31% (238/756) >= 35 years of age chose to have invasive testing as compared to only 11.2% (25/223) of those <35 years of age (p < 0.001). Of the screen-positive women, 71% (72/102) >= 35 years of age and 100% (2/2) <35 years of age chose to obtain invasive testing (p = 0.368). Conclusion First-trimester NT screening for Down syndrome (DS) enables a significant number of women over age 35 to lower the risk for DS several fold and avoid the risks of invasive testing. However, despite significant reductions in age-specific mid-trimester DS risks, a relatively high proportion of women >= 35 years of age still opted for invasive testing. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:119 / 123
页数:5
相关论文
共 24 条
[1]   Second trimester screening for Down's syndrome: 7 years experience [J].
Beaman, JM ;
Goldie, DJ .
JOURNAL OF MEDICAL SCREENING, 2001, 8 (03) :128-131
[2]  
BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x
[3]   A PROSPECTIVE TRIAL OF PRENATAL SCREENING FOR DOWN-SYNDROME BY MEANS OF MATERNAL SERUM ALPHA-FETOPROTEIN, HUMAN CHORIONIC-GONADOTROPIN, AND UNCONJUGATED ESTRIOL [J].
BURTON, BK ;
PRINS, GS ;
VERP, MS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (03) :526-530
[4]   Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis [J].
Caughey, AB ;
Kuppermann, M ;
Norton, ME ;
Washington, AE .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (05) :1239-1245
[5]   DETERMINANTS OF PARENTAL DECISIONS TO ABORT FOR CHROMOSOME-ABNORMALITIES [J].
DRUGAN, A ;
GREB, A ;
JOHNSON, MP ;
KRIVCHENIA, EL ;
UHLMANN, WR ;
MOGHISSI, KS ;
EVANS, MI .
PRENATAL DIAGNOSIS, 1990, 10 (08) :483-490
[6]  
DRUZIN ML, 1993, OBSTET GYNECOL, V81, P615
[7]  
Hafner E, 1998, PRENATAL DIAG, V18, P29, DOI 10.1002/(SICI)1097-0223(199801)18:1<29::AID-PD213>3.0.CO
[8]  
2-N
[9]   Decision analysis of prenatal testing for chromosomal disorders: What do the preferences of pregnant women tell us? [J].
Harris, RA ;
Washington, AE ;
Feeny, D ;
Kuppermann, M .
GENETIC TESTING, 2001, 5 (01) :23-32
[10]  
Kornman LH, 1996, PRENATAL DIAG, V16, P797, DOI 10.1002/(SICI)1097-0223(199609)16:9<797::AID-PD948>3.3.CO